Stomach Diseases  >>  oxaliplatin  >>  Phase 3
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
oxaliplatin / Generic mfg.
CLASSIC, NCT00411229: Capecitabine and Oxaliplatin Adjuvant Study in Stomach Cancer

Completed
3
1035
RoW
Capecitabine, Oxaliplatin
Sanofi, Hoffmann-La Roche
Stomach Neoplasms
11/12
11/12
NCT01662869 / 2012-001402-23: A Study of Onartuzumab in Combination With mFOLFOX6 in Participants With Metastatic HER2-Negative and MET-Positive Gastroesophageal Cancer

Checkmark ASCO 2015
May 2015 - May 2015: ASCO 2015
Checkmark P3 MetGastric MetMab + mFOLFOX6 trial for metastatic HER2-negative gastroesophageal cancer on hold
Apr 2014 - Apr 2014: P3 MetGastric MetMab + mFOLFOX6 trial for metastatic HER2-negative gastroesophageal cancer on hold
Checkmark ASCO 2013
More
Completed
3
564
US, Canada, Europe, RoW
5-Fluoruracil, Folinic acid, Onartuzumab, MetMAb, RO5490258, PRO143966, Oxaliplatin, Placebo
Hoffmann-La Roche, Genentech, Inc.
Gastric Cancer
12/15
12/15
NCT01824459: S-1+Oxaliplatin vs.S-1+Cisplatin First-line Treatment of Advanced or Recurrent Non-intestinal Type Gastric Adenocarcinoma Patients

Completed
3
576
RoW
S-1, Oxaliplatin, Cisplatin
Sun Yat-sen University, Taiho Pharmaceutical Co., Ltd.
Gastric Cancer
12/18
12/18

Download Options